^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CTB-006

    i
    Other names: CTB-006, CTB 006
    Associations

    News

    Trials
    Company:
    Sinotau Pharma
    Drug class:
    TRAIL R2 agonist
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors (AACR 2021)
    Addition of APG-1387 potentiated this effect, with the combination treatment leading to T/C values of 3% to 15%, and complete regression, PR, or stable disease in all treated tumors. In summary, our results suggest great potential of combination therapy with APG-1387 and CTB-006 for solid tumor therapy and deserves further clinical investigation.
    Preclinical
    |
    CASP3 (Caspase 3) • CASP8 (Caspase 8)
    |
    APG-1387 • CTB-006